For executives of Lexicon Pharmaceuticals Inc., the missed primary endpoint in the phase IIb Progress study testing pilavapadin, its non-opioid candidate, in adults with moderate to severe diabetic ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

3. CAS Reg. No. 163222-33-1. Suzetrigine 1 is a newly registered nonopioid pain medication. It was first described in world patent application WO2021113627 (2021) to inventor Steven Durrant at Vertex ...

The study compared Probudur with free bupivacaine and Pacira Pharmaceuticals Inc’s PCRX non-opioid analgesic pain killer, Exparel. Various concentrations of Probudur were injected into the ...

The study compared Probudur with free bupivacaine and Pacira Pharmaceuticals Inc’s (NASDAQ:PCRX) non-opioid analgesic pain killer, Exparel. Various concentrations of Probudur were injected into the ...

Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...

Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.